Final Program (updated: 09/06/16) Results and Interpretations of ASCO Presentations 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer 6 th European Post-Chicago Melanoma/Skin Cancer Meeting www.melanomaglobal2016.org Under the auspices of the European Association of Dermato-Oncology June 30 th – July 1 st , 2016 Munich, Germany Leonardo Royal Hotel Congress Presidents Axel Hauschild, Kiel, Germany Claus Garbe, Tuebingen, Germany
Transcript
Final Program (updated: 09/06/16)
Results and Interpretations of ASCO Presentations 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer
6 th European Post-Chicago Melanoma/Skin Cancer Meeting
www.melanomaglobal2016.orgUnder the auspices of the
European Association of Dermato-Oncology
June 30 th– July 1st, 2016Munich, Germany Leonardo Royal Hotel
Congress Presidents Axel Hauschild, Kiel, Germany
Claus Garbe, Tuebingen, Germany
WELCOME MESSAGE 01
PROGRAM AT A GLANCE 02
PROGRAM 04
Thursday, June 30th 04
Friday, July 1st 07
CONGRESS FACULTY 11
FLOOR PLAN 14
SATELLITE SYMPOSIA OVERVIEW 16
GENERAL INFORMATION 18
SPONSORS 21
REGISTRATION FORM 23
CONTENT
1
WELCOME MESSAGE
Dear colleagues and friends,
Since the first Post-Chicago Meeting on Melanoma/Skin Cancer took place in 2011, it has attracted up to 580 participants each year from all over the world. The interactive congress offers a comprehensive overview on all new developments in melanoma diagnostics and therapy and a direct communication with the world´s leading experts in these fields.
Presently, there are many new developments in melanoma diagnostics and treatment. New devices may enable a more precise diagnostics of primary melanoma and allow earlier detection. For metastatic melanoma, there is a rapid change of therapeutic approaches. New drugs like BRAF- and MEK-inhibitors and CTLA4 and PD1-antibodies are already established in melanoma treatment. However, it remains an open question how to combine them and how they should be sequentially applied. Additionally, the significance of other drugs and vaccines like T-VEC has still to be determined.
Nevertheless, it will be the main target for all of us to choose the right patients for the right drugs! The aim of the Interdisciplinary Global Conference on Developing New Treatments for Melanoma/Skin Can-cer in Munich is to grant a deep overall insight into the development of new drugs for melanoma and other cutaneous malignancies. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.
International key opinion leaders on melanoma will be invited to give an overview throughout speci-fied presentations, to present latest clinical trial results, and to discuss on exciting new drugs with the audience. In addition to the scientific value of this meeting, every participant may seize the given op-portunity to interact with experts in a familiar setting in one of the most interesting cities of Germany.
Please join us for this event and submit your own studies and case presentations as free communications and as posters.
We look forward to welcoming you in Munich in June 2016!
Claus Garbe, MDCongress President
Axel Hauschild, MDCongress President
2
PROGRAM AT A GLANCE
8:00
9:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
Opening of the conference
SYMPOSIUM IMy personal highlights at ASCO 2016
KEY NOTE LECTURE
SATELLITE SYMPOSIUM I with lunch (platinum sponsor)
SATELLITE SYMPOSIUM II (platinum sponsor)
SYMPOSIUM IVFrequent and rare adverse events of new drugs
SYMPOSIUM IIAdjuvant treatment of melanoma
PARALLEL SESSION IPrognostic and predictive markers for tumor response
08:30– 09:00 How does immune checkpoint inhibition work? Antoni Ribas, Los Angeles, USA
09:00– 09:30 Is cure of metastatic melanoma on the horizon? Caroline Robert, Paris, France
09:30–10:00 SATELLITE SYMPOSIUM III (platinum sponsor) (see page 14)
10:00 –10:30 COFFEE BREAK
10:30 –11:30 SATELLITE SYMPOSIUM IV (platinum sponsor) (see page 14)
11:30 –12:00 COFFEE BREAK
ROYAL BALLROOM
ROYAL BALLROOM
ROYAL BALLROOM
ROYAL BALLROOM
8
FRIDAY, JULY 1ST
12:00 –13:30 SATELLITE SYMPOSIUM V with lunch (platinum sponsor) (see page 14)
13:30 –14:50 SYMPOSIUM V Current Clinical Trials II
CHAIRPERSONS: CHRISTIAN BLANK, AMSTERDAM, NETHERLANDS CHRISTOPH HÖLLER, VIENNA, AUSTRIA
13:30-13:42 MAGE-A3 vaccination (DERMA-trial): Final results Brigitte Dréno, Nantes, France13:46–13:58 BRAF + MEK inhibition James Larkin, London, United Kingdom14:02–14:14 NEMO trial: Binimetinib for NRAS-mutated melanoma Reinhard Dummer, Zurich, Switzerland14:18–14:30 Combined immune checkpoint inhibition Christian Blank, Amsterdam, Netherlands14:34–14:46 Chemosaturation in liver metastasis Roland Kaufmann, Frankfurt, Germany
13:30–15:00 PARALLEL SESSION II EADO Forum: Our most interesting melanoma cases
CHAIRPERSONS: KETTY PERIS, ROME, ITALY IRIS ZALAUDEK, GRAZ, AUSTRIA
13:30–13:37 Case 1 Elisabeth Livingstone, Essen, Germany13:40–13:47 Case 2 Matilda Bylaite Bucinskiene, Vilnius, Lithuania 13:50–13:57 Case 3 Zeljko Mijuskovic, Belgrade, Serbia14:00–14:07 Case 4 Ketty Peris, Rome, Italy14:10–14:17 Case 5 Lidija Kandolf-Sekulovic, Belgrade, Serbia14:20–14:27 Case 6 Judith Oláh, Szeged, Hungary14:30–14:37 Case 7 Iris Zalaudek, Graz, Austria
14:40–14:47 Case 8 Petr Arenberger, Prague, Czech Republic
ROYAL BALLROOM
ROYAL BALLROOM
R1+R2
9
FRIDAY, JULY 1ST
ROYAL BALLROOM
ROYAL BALLROOM
15:00 –15:30 COFFEE BREAK
15:30 –17:00 SATELLITE SYMPOSIUM VI (platinum sponsor) (see page 14)
17:00 –18:25 SYMPOSIUM VI Standard of care for BRAF mutated melanoma? Pros and Cons
CHAIRPERSONS: SELMA UGUREL, ESSEN, GERMANY AXEL HAUSCHILD, KIEL, GERMANY
17:00 –17:25 My first choice: Immunotherapy Antoni Ribas, Los Angeles, USA
17:30 –17:55 My first choice: BRAF + MEK inhibition Dirk Schadendorf, Essen, Germany
18:00 –18:25 Round Table Discussion Australian View: Grant McArthur European View: Reinhard Dummer / Dirk Schadendorf US View: Sanjiv Agarwala / Antoni Ribas
17:00 –17:08 Efficacy of talimogene laherparepvec (T-VEC) combined with pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma: analysis of the MASTERKEY-265 phase 1b study Reinhard Dummer, Zurich, Switzerland
17:10 –17:18 Molecular characterization of the immune profile in the sentinel lymph node in melanoma is predictive of tumor status and survival Richard Essner, Los Angeles, USA
17:20 –17:28 Optimal Patient Selection for Immunotherapy in Melanoma using Tissue Phenomics Nathalie Harder, Munich, Germany
17:30 –17:38 Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067 Dirk Schadendorf, Essen, Germany
R1+R2
10
17:40 –17:48 Immunotherapy a good match for elderly melanoma patients Paul Lorigan, Manchester, United Kingdom
17:50 –17:58 The PI3K-AKT pathway – a therapeutic target in melanoma brain metastases Heike Niessner, Tuebingen, Germany
18:00 –18:08 Chemosaturation via percutaneous hepatic perfusion – an update on a single centre experience of treating metastatic uveal melanoma Christian Ottensmeier, Southampton, United Kingdom
18:10 –18:18 Two-year overall survival rates from a randomized phase II trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab in patients with advanced melanoma Michael Postow, New York, USA
Sanjiv S. Agarwala , MDProfessor of MedicineSt. Lukes Cancer Center, Temple University2145 Augusta DRCenter Valley PA 18034USAPhone: +1-610-297-0169 Email: [email protected]
Robert Andtbacka, MDAssociate Professor of Surgical OncologyDepartment of SurgeryUniversity of UtahHuntsman Cancer Institute2000 Circle of Hope DriveSalt Lake City, Utah 84112-5550USAPhone: +1 801 587 8808Email: [email protected]
Petr Arenberger, MDDepartment of Dermatology, CharlesUniversity, 3rd School of MedicineSrobarova 50CZ-100 34 PragueCzech RepublicPhone: +420-26716-3000Email: [email protected]
Paolo A. Ascierto, MDMelanoma, Cancer Immunotherapy and Innovative Therapy UnitIstituto Nazionale Tumori Fondazione “G. Pascale”Via Mariano Semmola80131 NaplesItalyPhone: +39-081-5903236Email: [email protected]
B
Carola Berking, MDProfessor of DermatologyDepartment of Dermatology and AllergologyUniversity Hospital Munich (LMU)Frauenlobstr. 9–11 80337 MunichGermanyPhone: +49-89-4400-56225Email: [email protected]
Christian Blank, MDThe Netherlands Cancer InstitutePlesmanlaan 121 1066 CX AmsterdamThe NetherlandsPhone: +31-20-512-2570Email: [email protected]
Matilda Bylaite-Bucinskiene, MDProfessor of DermatologyChairwoman of the Centre of Dermatovenereology President of Lithuanian Association of DermatovenereologistsVilnius University Hospital Santariskiu KlinikosKairiukscio str. 208411 VilniusLituaniaPhone: +370-5-2720385Email: [email protected]
D
Brigitte Dréno, MDProfessor of DermatologyChairman of the department of Dermatology, Director of the Unit of gene and Cell Therapy, Vice Dean for Research at the Faculty of Medicine Nantes FranceCHU Nantes Place Alexis Ricordeau44093 Cedex 01FrancePhone: +33-2-40083118Email: [email protected]
Reinhard Dummer, MDProfessor of DermatologyDepartment of DermatologyVice Chairman, University of Zurich HospitalGloriastrasse 318091 ZurichSwitzerlandPhone: +41-442552507Email: [email protected]
E
Thomas Eigentler, MDDepartment of DermatologyEberhard Karls UniversityLiebermeister Str. 2572076 TuebingenGermanyPhone: +49-7071-2985748Email: thomas.eigentler@ med.uni-tuebingen.de
G
Claus Garbe, MDProfessor of DermatologyDepartment of DermatologyEberhard Karls UniversityLiebermeister Str. 2572076 TuebingenGermanyPhone: +49-7071-2987110Email: [email protected]
Stephan Grabbe, MDProfessor of Dermatology, DirectorDepartment of DermatologyJohannes Gutenberg UniversityLangenbeckstr. 155131 MainzGermanyPhone: +49-6131-172910Email: [email protected]
Ralf Gutzmer, MDProfessor of DermatologySkin Cancer Center, Department of DermatologyHannover Medical SchoolCarl-Neuberg-Str. 130625 HannoverGermanyPhone: +49-511-532-0Email: [email protected]
H
Jessica Hassel, MDDepartment of Dermatology, University Hospital Heidelberg and Nationales Centrum für Tumor-erkrankungen (NCT)Im Neuenheimer Feld 46069120 Heidelberg GermanyPhone: +49-6221-5638503Email: [email protected]
Axel Hauschild, MDProfessor of DermatologyDepartment of DermatologyUniversity of KielSchittenhelmstr. 724105 KielGermanyPhone: +49-431-5971852Email: [email protected]
Lucie Heinzerling, MD, PhD, MPHProfessorDepartment of DermatologyUniversity Hospital of ErlangenUlmenweg 1891054 ErlangenGermanyPhone: +49-9131-8539037Email: [email protected]
12
Christoph Höller, MDProfessor of DermatologyDepartment of DermatologyMedical University of ViennaWaehringer Gürtel 18-201090 ViennaAustriaPhone: +43-1-404004786Email: [email protected]
K
Katharina Kähler, MDDepartment of DermatologyUniversity of KielSchittenhelmstr. 724105 KielGermanyPhone: +49-431-5971512Email: [email protected]
Lidija Kandolf-Sekulovic, MDDepartment of DermatologyMilitary Medical AcademyCrnotravska 17 11000 BelgradeSerbiaPhone: +381-113608583Email: [email protected]
Roland Kaufmann, MDProfessor of Dermatology, DirectorDepartment of DermatologyClinical Center J. W. Goethe UniversityTheodor-Stern-Kai 760590 Frankfurt am MainGermanyPhone: +49-69-63015311Email: [email protected]
John Kirkwood, MDUsher Professor of Medicine, Dermatology and Translational ScienceDirector Melanoma and Skin Cancer ProgramUniversity of Pittsburgh Hillman Cancer CenterLaboratory Suite L1.32c5117 Centre Avenue, Suite 1.32Pittsburgh PA 15213USAPhone: 001-412-623-7707Email: [email protected]
L
Jennifer Landsberg, MDDepartment of DermatologyUniversity of BonnSigmund-Freud-Straße 2553127 BonnGermanyPhone: +49-228-73-7021 Email: [email protected]
James Larkin, MDConsultant Medical OncologistThe Royal Marsden HospitalFulham RoadLondon, SW3 6JJUnited KingdomPhone: +44-207-8118576Email: [email protected]
Celeste Lebbé, MDProfessor of DermatologyDepartment of DermatologyHôpital Saint-Louis1, Avenue Claude-Vellefaux75010 ParisFrancePhone: +33-142494679Email: [email protected]
Elisabeth Livingstone, MDUniversity Hospital EssenHauttumorzentrumHufelandstr. 5545122 EssenGermanyPhone: +49-201-7232431Email: [email protected]
M
Michele Maio, MDProfessor of OncologyDepartment of Medical Oncology and ImmunotherapyUniversity Hospital of SienaStrada della Scotte no. 1453100 SienaItalyPhone: +39-0577586336Email: [email protected]
Josep Malvehy, MDDirector of the Melanoma UnitDepartment of DermatologyHospital Clinic of BarcelonaC/Villarroel 17008036 BarcelonaSpainPhone: +34-933638920Email: [email protected]
Grant McArthur, MDProfessor of MedicineHead Cancer Therapeutics ProgramHead Skin and Melanoma ServiceDivisions of Cancer Medicine and Re-searchPeter MacCallum Cancer CentreLocked Bag 1A’Beckett StMelbourne 8006AustraliaPhone: +61-3-9656-3649Email: [email protected]
Friedegund Meier, MDProfessor of DermatooncologyDepartment of Dermatology University Hospital Carl Gustav Carus Technical University Dresden Fetscherstr. 7401307 DresdenGermanyPhone: +49-351-4583677Email: [email protected]
Olivier Michielin, MDHead of Melanoma ClinicDepartment of OncologySwiss Institute of BioinformaticsLudwig Institute1015 Lausanne SwitzerlandPhone: +41-21-692-4053Email:[email protected]
Zeljko Mijuskovic, MDPresident of Serbian Association of DermatovenereologistsClinic of DermatovenereologyFaculty of Medicine, Military Medical Academy17 Crnotravska11000 Belgrade SerbiaPhone: +381-11-3609183Email: [email protected]
Peter Mohr, MDCenter of DermatologyElbe Klinikum BuxtehudeAm Krankenhaus 121614 BuxtehudeGermanyPhone: +49-41617036209/-6250Email: [email protected]
O
Judit Oláh, MDDepartment of DermatologyUniversity of SzegedKoranyi Fasor 63720 SzegedHungaryPhone: +36-62-545984Email: [email protected]
P
Hubert Pehamberger, MDProfessor and ChairmanDepartment of DermatologyMedical University of ViennaWaehringer Guertel 18-201090 ViennaAustriaPhone: +43-1-404007710Email: hubert.pehamberger@ meduniwien.ac.at
13
Ketty Peris, MDDepartment of DermatologyCatholic University of RomeLargo a Gemelli, 800168 RomeItalyPhone: +39-630154227Email: [email protected]
Michael A. Postow, MDMemorial Sloan Kettering Cancer Center1275 York AvenueNew York, NY 10065USAPhone: +1-646-888-4589Email: [email protected]
Q
Paola Queirolo, MDPresidente IMIUOC Oncologia MedicaIRCCS San Martino-ISTGenovaItalyEmail: [email protected]
R
Antoni Ribas, MDProfessor of Medicine, Surgery and Mo-lecular and Medical PharmacologyUniversity of California Los AngelesUCLA Medical Center Hematology/ Oncology100 UCLA Medical Plaza, Suite 550Los Angeles, 90095USAPhone: +1-310-794-4955 Email: [email protected]
Caroline Robert MD, PhDHead DermatologyGustave Roussy Institute114 rue Edouard Vaillant 94801 VillejuifFrancePhone: +33-1-4211-64-97 Email: [email protected]
S
Dirk Schadendorf, MDProfessor of DermatologyDepartment of DermatologyUniversity Hospital EssenHufelanstr. 5545147 EssenGermanyPhone: +49-201-7232430Email: [email protected]
Selma Ugurel, MDProfessor of DermatologyDepartment of DermatologyUniversity Hospital EssenHufelandstr. 5545122 EssenGermanyPhone: +49-201-7234714Email: [email protected]
W
Benjamin Weide, MDDepartment of DermatologyEberhard Karls UniversityLiebermeister Str. 2572076 TuebingenGermanyPhone: +49-7071-2984555Email: benjamin.weide@ med.uni-tuebingen.de
Z
Iris Zalaudek, MDDivision of Dermatology and Venerology Non-Melanoma Skin Cancer UnitMedical University of GrazAuenbruggerplatz 88036 GrazAustriaPhone: +43-6763328269Email: [email protected]
14
Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
The � rst anti–PD-1 to demonstrate superior overall survival vs ipilimumab1
KEYTRUDA is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic melanoma.
For patients with advanced melanoma
KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic melanoma who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA at a dose of 10 mg/kg* every 2 (n=279) or 3 weeks (n=277) or ipilimumab (n=278). The primary ef� cacy outcome measures were overall survival (OS) and progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1
a In intent-to-treat population. b Median not reached.PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=con� dence interval.* The recommended dosage according to Prescribing Information is 2 mg/kg every 3 weeks.
HR (95% CI) Risk reduction vs ipilimumab vs ipilimumab P value
Kaplan-Meier curve for overall survival by treatment arm.
68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b
KEYTRUDA®
KEYTRUDA® 50 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungWirkstoff: Pembrolizumab Zus.: 1 Durchstechfl. enth.: Arzneil. wirks. Bestandt.: 50 mg Pembrolizumab. Nach Rekon-stitution enth. 1 ml Lsg. 25 mg Pembrolizumab. Sonst. Bestandt.: L-Histidin, L-Histidinhydrochlorid-Monohydrat, Sucrose, Polysorbat 80. Anw.: Als Monother. zur Behandl. d. fortgeschrittenen (nicht resezierbaren od. metastasie-renden) Melanoms bei Erw. Gegenanz.: Überempf.-keit geg. d. Wirkstoff od. e. d. sonst. Bestandt. Stillzeit. Vorsicht bei: Schwerer Einschränk. d. Nierenfunkt.; moderater od. schwerer Einschränk. d. Leberfunkt (nur begrenzte Daten). Melanom d. Auges (limitierte Daten zu Sicherh. u. Wirksamk.). Kdr. u. Jugendl. < 18 J. (keine Daten). Behandl. nach Risikoabwägung (keine Daten) bei Pat. mit: HIV-, Hepatitis-B- od. Hepatitis-C-Infekt.; akt., system. Autoimmunerkrank.; Pneumonitis od. schwerer Überempf.-keit geg. e. and. monoklonalen Antikörper in d. Anamnese; laufender Ther. mit Immun suppressiva; schweren immunvermittelten NW unter Ipilimumab in d. Anamnese (jegliche Grad 4 od. Grad 3 Toxizität), d. eine Kortikosteroid-Behandl. über mehr als 12 Wo. erforderte (mehr als 10 mg/Tag Prednison od. Äqui-valent in entspr. Dosierung); aktiv. Infekt.-erkrank. Schwangersch. Nebenw.: Sehr häufig: Diarrhö; Übelk. Hautaus-schl. (einschl. erythemat., follikul., general., makulärer, makulo-papulöser, papulöser, juck., vesikul. Hautausschl.); Pruritus (einschl. Urtikaria, general. Pruritus). Arthralgie. Müdigk./Erschöpf. Häufig: Anämie; Thrombozytopenie. Hy-pophysitis (einschl. Hypophysenunterfunkt.); Hyper thyreose; Hypothyreose. Vermind. Appetit; Dehydrierung. Kopf-schm.; Dysgeusie; periph. Neuropathie; Schwindel; Parästhesie. Trock. Augen. Vertigo. Hitzewall. Pneumonitis (ein-schl. interstit. Lungenerkrank.); Dyspnoe; Husten. Kolitis (einschl. mikroskop. Kolitis, Enterokolitis); Erbr.; Abdominalschm. (einschl. abdominaler Beschw., Oberbauch- u. Unterbauchschm.); Obstipat.; Mundtrockenh.; auf-geblähtes Abdomen. Schwere Hautreakt. (einschl. exfoliativ. Dermatitis, Erythema multiforme, exfoliativ. Hautaus-schl., SJS, Grad ≥ 3 Pruritus, Hautausschl., general. Hautausschl., makulo-papulöser Hautausschl.); Vitiligo (einschl. Hautdepigment.); Hauttrockenh.; Erythem; Ekzem; Hyperhidrose (einschl. Nachtschweiß); Hypopigment. d. Haut; Alopezie. Myalgie; Muskelschw.; muskuloskelett. Schm. (einschl. muskuloskelett. Beschw.); Schm. in d. Extremitäten; Rückenschm.; Arthritis; Muskelkrämpfe; muskuloskelett. Steifheit. Asthenie; Fieber; Schleimhautentzünd.; periph. Ödeme; grippeähnl. Erkrank.; Schüttelfrost. Erhöh. Werte von: AST; ALT; alkal. Phosphatase im Blut; Gewichtsab-nahme. Infus.-bedingte Reakt. (einschl. Überempf.-keit geg. d. AM, anaphylakt. Reakt., Überempf.-keit, „Cytokine-Re-lease-Syndrom“). Gelegentl.: Divertikulitis; Pneumonie; Konjunktivitis; Herpes zoster; Candida-Infekt.; Influenza; Harnwegsinfekt.; Herpes (simplex) im Mundbereich; Nasopharyngitis; Follikulitis. Tumorschm. Neutropenie; Lympho-penie; Leukopenie; Eosinophilie. Nebenniereninsuff.; Thyreoiditis (einschl. autoimmuner Thyreoiditis). Typ-I-Diabetes mellitus; Hyponatriämie; Hypokaliämie; Hyperglykämie; Hypophosphatämie; Hypalbuminämie; Hypertriglyzeridämie; Hypokalz ämie; Hypomagnesiämie; Hypercholesterinämie; Hyperkalzämie; Hyperurikämie. Verwirrtheitszustand (ein-schl. Desorientier.); Schlaflosigk.; Ängstlichk.; vermind. Libido; Depress. Hypoästhesie; Lethargie; Neuralgie; periphere sensor. Neuropathie; Hypogeusie; Restless-Legs-Syndrom; Hypotonie; Gedächtnisstör.; Tremor; Gleichgewichtsstör.;
Aufmerksamkeitsstör.; Hyperästhesie; Hypersomnie. Uveitis (einschl. Iritis u. Irido cyclitis); Augenschm.; Sehstör.; Juckreiz d. Augen; Verschwommensehen; erhöh. Tränensekret.; okul. Hyperämie; Augenreiz.; Verfärb. d. Wimpern; Photophobie; Mouches volantes. Perikarderguss; Palpitat. Hypotonie; Hitzegefühl/Flush; Raynaud-Syndrom. Pleu-raschm.; Dysphonie; Giemen; verstopfte Nase; Schm. im Mundrachenraum; Hämoptoe; produkt. Husten; schmerzhafte Atmung; Epistaxis; Nasenlaufen; Niesen. Pankreatitis; Dysphagie; Schm. im Mund; gastroösophag. Refluxkrank.; Dyspepsie; Gastritis; Hämorrhoiden; Zahnerkrank.; Flatulenz.; Zahnfleischschm.; Stomatitis; Cheilitis. Hepatitis (ein-schl. auto immune Hepatitis); Cholestase. Palmoplant. Erythrodysästhesie-Syndrom; Psoriasis; akneiforme Dermatitis; Dermatitis; Farbveränd. d. Haare; Papeln; photosensitive Hautreakt.; Hauterkrank.; Hautläsion; Hautgeschwülste; abnormes Haarwachstum; lichenoide Keratose; Hautverfärb.; Hyperpigment. d. Haut; Erythema nodosum; Pigment-stör.; Hautgeschwüre. Myositis (einschl. Myopathie u. Rhabdomyolyse); Steifheit d. Gelenke; Schwell. d. Gelenke; Polymyalgia rheumatica; Polyarthritis; Schm. im Kiefer; Knochenschm.; Flankenschm.; Synovitis; Nackenschm.; Mus-kelzuck. Nephritis (einschl. Autoimmunnephritis u. tubulointerstit. Nephritis); akute Niereninsuff.; Niereninsuff.; chron. Niereninsuff.; Pollakisurie; Dysurie. Unterleibsschm.; erektile Dysfunktion; Menorrhagie. General. Ödeme; Schm.; Schm. im Brustkorb; Entzünd.; Gangstör.; Beschw. im Brustkorb; Wärmeunverträglichk.; Unwohlsein; Ödeme; Gesicht-södem; Xerose; Hitze gefühl; Durst. Erhöh. Werte von: Kreatinphosphokinase im Blut; GGT; Amylase; Blutglukose; Kreatinin im Blut; Bilirubin im Blut; TSH im Blut; Trijodthyronin; Triglyzeriden im Blut; Cholesterin im Blut; freiem Thyroxin; Transaminasen; Kalzium im Blut; erniedr. Werte von: TSH im Blut; Thyroxin. Gewichtszunahme. Selten: Akrochordon; Neoplasmaschwell. Immunthrombozytopen. Purpura; hämolyt. Anämie; Panzytopenie. Auto-immunerkrank. Affekt. Stör.; Agitiertheit; Halluzinat.; Trance. Hirnödem; Enzephalopathie; Epilepsie; nicht infekt. Meningitis; Myasthenie-Syndrom; Krämpfe; Dysarthrie; fokale Krampfanfälle; Synkope. Doppelt sehen; Erkrank. d. Auges; Erkrank. d. Augenlids; Makula-Degeneration; periorbit. Ödem; Photopsie. Lagerungsschwindel. Vorhofflim-mern. Hypertonie; Lymphödem; Vaskulitis. Pleuraerguss; Kongestion d. Atemwege. Dünndarmperforation; Blutungen im oberen GIT; Oberbauchbeschw.; Glossitis; Zahndemineral. Akne; Kontaktdermatitis. Plant. Fasziitis; Arthropathie; Sehnenschm.; Sehnenentzünd.; Sehnenscheidenentzünd. Harninkont. Dysmenorrhö; Hämatospermie; genitaler Juck-reiz; skrotales Erythem. Entzünd.-schm.; lokale Schwell.; lokal begrenztes Ödem; Reakt. an d. Infus.-stelle; Schwell. Autoantikörper-positiv; QT-Verlängerung im EKG; verläng. aktiv. part. Thromboplastinzeit; erniedr. Testosteronwerte im Blut; erhöh. Harnsäurewerte im Blut; erhöh. Werte von CRP; erhöh. Anzahl an Eosinophilen. Zusätzl.: diabet. Ke-toazidose. Opt. Neuritis. Ther.-bedingte Antikörper. Warnhinw.: Zuverlässige Verhütungsmethode b. Frauen im ge-bährf. Alter bis 4 Mon. nach Behandl.-ende. Verschreibungspflichtig. Stand: 07/2015Bitte lesen Sie vor Verordnung von KEYTRUDA® die Fachinformation! Pharmazeutischer Unternehmer: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BUVereinigtes KönigreichLokaler Ansprechpartner: MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar
ONCO-1172474-0000.indd 1 21.01.16 18:47
LEONARDO ROYAL HOTELMUNICH
UNTERGESCHOSS/BASEMENT
ERDGESCHOSS/GROUND FLOOR
Lobby
Ein
fah
rt T
iefg
ara
ge
/a
cc
ess
un
de
rgro
un
d p
ark
ing
Hoteleingang/hotel entrance
LiftsDavidoffLounge
WC/toilet
BackOffice
Serv
ice
Service
Terrasse/terrace
Terrasse/terrace
Foyer
R1
R2
R3
R5
R6 R7
Busin
ess
Ce
nte
r
Moosacher Straße 90
R4
kün
stlic
he
r Wa
sse
rlau
f/a
rtifi
cia
l wa
ter p
oin
t
Speaker-Preview-
Room
Re
ce
ptio
nD
esk
RegistrationDesk
FLOOR PLAN
15
Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532.
The � rst anti–PD-1 to demonstrate superior overall survival vs ipilimumab1
KEYTRUDA is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic melanoma.
For patients with advanced melanoma
KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic melanoma who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma were not required to have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA at a dose of 10 mg/kg* every 2 (n=279) or 3 weeks (n=277) or ipilimumab (n=278). The primary ef� cacy outcome measures were overall survival (OS) and progression-free survival (PFS; as assessed by Integrated Radiology and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1
a In intent-to-treat population. b Median not reached.PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=con� dence interval.* The recommended dosage according to Prescribing Information is 2 mg/kg every 3 weeks.
HR (95% CI) Risk reduction vs ipilimumab vs ipilimumab P value
Kaplan-Meier curve for overall survival by treatment arm.
68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b
KEYTRUDA®
KEYTRUDA® 50 mg Pulver für ein Konzentrat zur Herstellung einer InfusionslösungWirkstoff: Pembrolizumab Zus.: 1 Durchstechfl. enth.: Arzneil. wirks. Bestandt.: 50 mg Pembrolizumab. Nach Rekon-stitution enth. 1 ml Lsg. 25 mg Pembrolizumab. Sonst. Bestandt.: L-Histidin, L-Histidinhydrochlorid-Monohydrat, Sucrose, Polysorbat 80. Anw.: Als Monother. zur Behandl. d. fortgeschrittenen (nicht resezierbaren od. metastasie-renden) Melanoms bei Erw. Gegenanz.: Überempf.-keit geg. d. Wirkstoff od. e. d. sonst. Bestandt. Stillzeit. Vorsicht bei: Schwerer Einschränk. d. Nierenfunkt.; moderater od. schwerer Einschränk. d. Leberfunkt (nur begrenzte Daten). Melanom d. Auges (limitierte Daten zu Sicherh. u. Wirksamk.). Kdr. u. Jugendl. < 18 J. (keine Daten). Behandl. nach Risikoabwägung (keine Daten) bei Pat. mit: HIV-, Hepatitis-B- od. Hepatitis-C-Infekt.; akt., system. Autoimmunerkrank.; Pneumonitis od. schwerer Überempf.-keit geg. e. and. monoklonalen Antikörper in d. Anamnese; laufender Ther. mit Immun suppressiva; schweren immunvermittelten NW unter Ipilimumab in d. Anamnese (jegliche Grad 4 od. Grad 3 Toxizität), d. eine Kortikosteroid-Behandl. über mehr als 12 Wo. erforderte (mehr als 10 mg/Tag Prednison od. Äqui-valent in entspr. Dosierung); aktiv. Infekt.-erkrank. Schwangersch. Nebenw.: Sehr häufig: Diarrhö; Übelk. Hautaus-schl. (einschl. erythemat., follikul., general., makulärer, makulo-papulöser, papulöser, juck., vesikul. Hautausschl.); Pruritus (einschl. Urtikaria, general. Pruritus). Arthralgie. Müdigk./Erschöpf. Häufig: Anämie; Thrombozytopenie. Hy-pophysitis (einschl. Hypophysenunterfunkt.); Hyper thyreose; Hypothyreose. Vermind. Appetit; Dehydrierung. Kopf-schm.; Dysgeusie; periph. Neuropathie; Schwindel; Parästhesie. Trock. Augen. Vertigo. Hitzewall. Pneumonitis (ein-schl. interstit. Lungenerkrank.); Dyspnoe; Husten. Kolitis (einschl. mikroskop. Kolitis, Enterokolitis); Erbr.; Abdominalschm. (einschl. abdominaler Beschw., Oberbauch- u. Unterbauchschm.); Obstipat.; Mundtrockenh.; auf-geblähtes Abdomen. Schwere Hautreakt. (einschl. exfoliativ. Dermatitis, Erythema multiforme, exfoliativ. Hautaus-schl., SJS, Grad ≥ 3 Pruritus, Hautausschl., general. Hautausschl., makulo-papulöser Hautausschl.); Vitiligo (einschl. Hautdepigment.); Hauttrockenh.; Erythem; Ekzem; Hyperhidrose (einschl. Nachtschweiß); Hypopigment. d. Haut; Alopezie. Myalgie; Muskelschw.; muskuloskelett. Schm. (einschl. muskuloskelett. Beschw.); Schm. in d. Extremitäten; Rückenschm.; Arthritis; Muskelkrämpfe; muskuloskelett. Steifheit. Asthenie; Fieber; Schleimhautentzünd.; periph. Ödeme; grippeähnl. Erkrank.; Schüttelfrost. Erhöh. Werte von: AST; ALT; alkal. Phosphatase im Blut; Gewichtsab-nahme. Infus.-bedingte Reakt. (einschl. Überempf.-keit geg. d. AM, anaphylakt. Reakt., Überempf.-keit, „Cytokine-Re-lease-Syndrom“). Gelegentl.: Divertikulitis; Pneumonie; Konjunktivitis; Herpes zoster; Candida-Infekt.; Influenza; Harnwegsinfekt.; Herpes (simplex) im Mundbereich; Nasopharyngitis; Follikulitis. Tumorschm. Neutropenie; Lympho-penie; Leukopenie; Eosinophilie. Nebenniereninsuff.; Thyreoiditis (einschl. autoimmuner Thyreoiditis). Typ-I-Diabetes mellitus; Hyponatriämie; Hypokaliämie; Hyperglykämie; Hypophosphatämie; Hypalbuminämie; Hypertriglyzeridämie; Hypokalz ämie; Hypomagnesiämie; Hypercholesterinämie; Hyperkalzämie; Hyperurikämie. Verwirrtheitszustand (ein-schl. Desorientier.); Schlaflosigk.; Ängstlichk.; vermind. Libido; Depress. Hypoästhesie; Lethargie; Neuralgie; periphere sensor. Neuropathie; Hypogeusie; Restless-Legs-Syndrom; Hypotonie; Gedächtnisstör.; Tremor; Gleichgewichtsstör.;
Aufmerksamkeitsstör.; Hyperästhesie; Hypersomnie. Uveitis (einschl. Iritis u. Irido cyclitis); Augenschm.; Sehstör.; Juckreiz d. Augen; Verschwommensehen; erhöh. Tränensekret.; okul. Hyperämie; Augenreiz.; Verfärb. d. Wimpern; Photophobie; Mouches volantes. Perikarderguss; Palpitat. Hypotonie; Hitzegefühl/Flush; Raynaud-Syndrom. Pleu-raschm.; Dysphonie; Giemen; verstopfte Nase; Schm. im Mundrachenraum; Hämoptoe; produkt. Husten; schmerzhafte Atmung; Epistaxis; Nasenlaufen; Niesen. Pankreatitis; Dysphagie; Schm. im Mund; gastroösophag. Refluxkrank.; Dyspepsie; Gastritis; Hämorrhoiden; Zahnerkrank.; Flatulenz.; Zahnfleischschm.; Stomatitis; Cheilitis. Hepatitis (ein-schl. auto immune Hepatitis); Cholestase. Palmoplant. Erythrodysästhesie-Syndrom; Psoriasis; akneiforme Dermatitis; Dermatitis; Farbveränd. d. Haare; Papeln; photosensitive Hautreakt.; Hauterkrank.; Hautläsion; Hautgeschwülste; abnormes Haarwachstum; lichenoide Keratose; Hautverfärb.; Hyperpigment. d. Haut; Erythema nodosum; Pigment-stör.; Hautgeschwüre. Myositis (einschl. Myopathie u. Rhabdomyolyse); Steifheit d. Gelenke; Schwell. d. Gelenke; Polymyalgia rheumatica; Polyarthritis; Schm. im Kiefer; Knochenschm.; Flankenschm.; Synovitis; Nackenschm.; Mus-kelzuck. Nephritis (einschl. Autoimmunnephritis u. tubulointerstit. Nephritis); akute Niereninsuff.; Niereninsuff.; chron. Niereninsuff.; Pollakisurie; Dysurie. Unterleibsschm.; erektile Dysfunktion; Menorrhagie. General. Ödeme; Schm.; Schm. im Brustkorb; Entzünd.; Gangstör.; Beschw. im Brustkorb; Wärmeunverträglichk.; Unwohlsein; Ödeme; Gesicht-södem; Xerose; Hitze gefühl; Durst. Erhöh. Werte von: Kreatinphosphokinase im Blut; GGT; Amylase; Blutglukose; Kreatinin im Blut; Bilirubin im Blut; TSH im Blut; Trijodthyronin; Triglyzeriden im Blut; Cholesterin im Blut; freiem Thyroxin; Transaminasen; Kalzium im Blut; erniedr. Werte von: TSH im Blut; Thyroxin. Gewichtszunahme. Selten: Akrochordon; Neoplasmaschwell. Immunthrombozytopen. Purpura; hämolyt. Anämie; Panzytopenie. Auto-immunerkrank. Affekt. Stör.; Agitiertheit; Halluzinat.; Trance. Hirnödem; Enzephalopathie; Epilepsie; nicht infekt. Meningitis; Myasthenie-Syndrom; Krämpfe; Dysarthrie; fokale Krampfanfälle; Synkope. Doppelt sehen; Erkrank. d. Auges; Erkrank. d. Augenlids; Makula-Degeneration; periorbit. Ödem; Photopsie. Lagerungsschwindel. Vorhofflim-mern. Hypertonie; Lymphödem; Vaskulitis. Pleuraerguss; Kongestion d. Atemwege. Dünndarmperforation; Blutungen im oberen GIT; Oberbauchbeschw.; Glossitis; Zahndemineral. Akne; Kontaktdermatitis. Plant. Fasziitis; Arthropathie; Sehnenschm.; Sehnenentzünd.; Sehnenscheidenentzünd. Harninkont. Dysmenorrhö; Hämatospermie; genitaler Juck-reiz; skrotales Erythem. Entzünd.-schm.; lokale Schwell.; lokal begrenztes Ödem; Reakt. an d. Infus.-stelle; Schwell. Autoantikörper-positiv; QT-Verlängerung im EKG; verläng. aktiv. part. Thromboplastinzeit; erniedr. Testosteronwerte im Blut; erhöh. Harnsäurewerte im Blut; erhöh. Werte von CRP; erhöh. Anzahl an Eosinophilen. Zusätzl.: diabet. Ke-toazidose. Opt. Neuritis. Ther.-bedingte Antikörper. Warnhinw.: Zuverlässige Verhütungsmethode b. Frauen im ge-bährf. Alter bis 4 Mon. nach Behandl.-ende. Verschreibungspflichtig. Stand: 07/2015Bitte lesen Sie vor Verordnung von KEYTRUDA® die Fachinformation! Pharmazeutischer Unternehmer: Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BUVereinigtes KönigreichLokaler Ansprechpartner: MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540 Haar
ONCO-1172474-0000.indd 1 21.01.16 18:47
16
THURSDAY, JUNE 30TH
12:00 –13:30 SATELLITE SYMPOSIUM I with lunch Amgen (platinum sponsor) ROYAL BALLROOM
Unlocking antigens to ignite tumor immunity in melanomaCHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
12:00–12:10 Where we are now with melanoma treatment? Axel Hauschild, Kiel, Germany
12:10–12:45 Talimogene laherparepvec (‘T-VEC’)*: from concept to clinical trials Robert Andtbacka, Salt Lake City, USA Josep Malvehy, Barcelona, Spain
12:45–13:20 Practical considerations when using T-VEC: a case-based discussion Robert Andtbacka, Salt Lake City, USA Josep Malvehy, Barcelona, Spain
13:20–13:30 Future perspectives for melanoma and beyond Axel Hauschild, Kiel, Germany
* Subject to additional monitoring.
This will allow quick identification of new safety information.
15:00 –16:30 SATELLITE SYMPOSIUM II Bristol-Myers Squibb (platinum sponsor) ROYAL BALLROOM
The I-O approach in advanced melanoma – from mono- to combination-therapyCHAIRPERSON: CLAUS GARBE, TUEBINGEN, GERMANY
15:00–15:30 Checkpoint modifiers in advanced melanoma – from mono- to combination-therapy James Larkin, London, United Kingdom
15:30–16:00 Therapy of patients with advanced melanoma – an individual approach Peter Mohr, Buxtehude, Germany
16:00–16:30 Panel discussion & Final discussion Claus Garbe, Tuebingen, Germany James Larkin, London, United Kingdom Peter Mohr, Buxtehude, Germany and the audience
SATELLITE SYMPOSIA OVERVIEW
17
FRIDAY, JULY 1ST
09:30 –11:30 SATELLITE SYMPOSIUM III and IV Roche (platinum sponsor) ROYAL BALLROOM
Your opinion matters – An interactive panel discussion on: Hot topics of targeted therapies in BCC and melanomaCHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
09:30–10:00 Are there new therapeutic approaches for hedgehoc inhibitors in BCC? Ralf Gutzmer, Hannover, Germany
10:00–10:30 Coffee Break10:30–11:30 The future of targeted therapies in melanoma?
Olivier Michielin, Lausanne, Switzerland Reinhard Dummer, Zurich, Switzerland Carola Berking, Munich, Germany Grant McArthur, Melbourne, Australia Christian Blank, Amsterdam, The Netherlands
12:00 –13:30 SATELLITE SYMPOSIUM V with lunch MSD (platinum sponsor) ROYAL BALLROOM
Integrating immuno-oncology therapies into clinical practice: An expert discussion CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY
12:00–12:05 Welcome and Introduction Axel Hauschild, Kiel, Germany
12:05–12:45 Initiating treatment with checkpoint inhibitor monotherapy or combinations Antoni Ribas, Los Angeles, USA Caroline Robert, Paris, France
12:45–13:20 Starting treatment with kinase inhibitors or immunotherapy Grant McArthur, Melbourne, Australia Peter Mohr, Buxtehude, Germany
13:20–13:30 Q & A session panel and concluding remarks
15:30 –17:00 SATELLITE SYMPOSIUM VI Novartis (platinum sponsor) ROYAL BALLROOM
A new era: Achieving personalized medicine in BRAF V600-mutant metastatic melanomaCHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY
15:40–16:00 BRAF V600 mutated metastatic melanoma: Our current understanding of the disease Christoph Höller, Vienna, Austria
16:00–16:20 Practicing individualized treatment in the clinic Paola Queirolo, Genova, Italy
16:20–16:40 Onwards and upwards: A look to the future Caroline Robert, Paris, France
16:40-16:55 Q & A with the faculty All
16:55-17:00 Wrap up and close Dirk Schadendorf, Essen, Germany
18
GENERAL INFORMATION
Congress VenueLeonardo Royal Hotel Munich, Moosacher Straße 90, 80809 Munich Phone: +49 (0)89 2885380, E-Mail: [email protected]/Leonardo_Royal_Hotel_Munich
Congress DateJune 30th–July 1st, 2016
Registration and Information DeskThe registration desk is situated at the ground floor of the Leonardo Royal Hotel to the left of the reception.
Registration Desk Opening HoursWednesday, June 29th, 2016 17:00–19:00 (early check-in) Thursday, June 30th, 2016 08:00–20:00Friday, July 1st, 2016 07:00–20:00
AccomodationIndividual hotel reservation: Please contact the congress hotel or one of the hotels nearby directly for yourindividual room bookings. MedConcept has reserved a limited number of rooms under the reference “EuropeanPost-Chicago Meeting 2016” in the following hotels:
Leonardo Royal Hotel Munich****Moosacher Str. 90, 80809 MunichPhone: +49 (0)89 62039779, Fax: +49 (0)89 62039717, E-Mail: [email protected] per standard room and night: 159 Euro single and 180 Euro double, breakfast includedBooking deadline: May 24th, 2016
Four Points By Sheraton München Olympiapark****Helene-Meyer-Ring 12, 80809 MunichPhone: +49 (0)89 35751750, Fax: +49 (0)89 35751755, E-Mail: [email protected] per standard room and night: 139 Euro single and 159 Euro double, breakfast includedBooking deadline: May 29th, 2016Distance to Leonardo Royal Hotel: 1 km
All booking of rooms only according to availability! All rates include 19 % VAT!
Call for AbstractsAll those interested in presenting abstracts at the 6th European Post-Chicago Melanoma Meeting are invited tosubmit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presenta-tion during the Free Communications Sessions. The best poster on display will be awarded during the congresson July 1st at 10:25 with a poster award of 1.000 Euro. The acceptance of an abstract does not include thecongress registration. Abstracts can be submitted online at www.melanomaglobal2016.org.
Deadline Abstract Submission: May 8th, 2016
19
CME CreditsThe 6th European Post-Chicago Melanoma/Skin Cancer Meeting: Results and Interpretations of ASCO Presenta-tions 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The 6th European Post-Chicago Melanoma/Skin Cancer Meeting: Results and Interpretations of ASCO Presenta-tions 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Asso-ciation, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certifica-tion Program of The Royal College of Physicians and Surgeons of Canada.
For German participants:
This program has been accredited by the Bavarian Medical Chamber with 12 German credit points (category B, 6 points on Thursday, 6 points on Friday).
How to receive your CME Credits
To obtain CME credits please fill in the evaluation form, which you will find in your congress bag and in the meeting rooms. To get your Certificate of Attendance with the CME credits please return the evaluation form duly filled in to the registration desk.
Cancellation PolicyCancellations must be received in writing by May 1st, 2016. No refunds will be granted after that date. To cancel a registration, please send an email to [email protected] and include “European Post-Chicago Melanoma Meeting 2016 Cancellation” in the subject line. A processing fee of 30 Euro will be deducted from each can-celled registration.
Substitutions (new ticket holder must come from the same institution) are possible and must be received in writ-ing by June 19th, 2016. To substitute a registration please send an email including the name of the original reg-istrant and the name of the person substituting to [email protected] and include “European Post-Chicago Melanoma Meeting 2016 Substitution” in the subject line.
The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.
ExhibitionA commercial exhibition will be held at the congress venue, close to the main rooms.
Exhibition Opening HoursThursday, June 30th, 2016 09:00–18:30Friday, July 1st, 2016 07:30–18:30
Language and TranslationThe official language of the meeting will be English. Simultaneous translation will not be provided.
20
InsuranceThe Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements in respect to health and travel insurance.
Passport and VisaFor most nationalities visas are not required for entering Germany. For further information about visa and passport please contact the German embassy in your country. If an invitation letter for visa purposes is required please contact MedConcept.
RegistrationPlease visit the congress website www.melanomaglobal2016.org for online registration or fill out the registration form on the last page of the program.
Registration Fees
Early registration till April 5th
From April 6th till June 19th
On site
Full Delegates 300 Euro 400 Euro 500 Euro
Doctors in training* and Eastern European Countries 200 Euro 250 Euro 300 Euro
Day Ticket 150 Euro 200 Euro 250 Euro
*Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-30
After June 19th all registrations have to be on-site at the meeting venue.
Important DatesEarly Registration Fee: till April 5th, 2016Deadline Abstract Submission: May 8th, 2016Notification of Acceptance of Abstracts: May 23rd, 2016Closing of Pre-Registration: June 19th, 2016
Congress Organization
Gesellschaft für medizinische Projekte mbHFriedenstraße 58 · 15366 Neuenhagen bei Berlin, Germany [email protected] · www.medconcept.org Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40
120,750 Euro Platinum Sponsorship incl. Meeting Room
SPONSORS
FURTHER SPONSORSDelcath Systems Limited
medac GmbH
Philogen S.p.A.
120,000 Euro Platinum Sponsorship
STRONGER TOGETHER
Combine COTELLIC with Zelboraf to achieve powerful efficacy in patients with BRAF V600(+) metastatic melanoma1
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.Cotellic® 20 mg film-coated tablets. Active substance: cobimetinib. Composition: Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib. Other ingredients: tablet core: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate; tablet coating: Poly(vinyl alcohol), titanium dioxide, macrogol and talc. Therapeutic indication: Cotellic is used in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Contraindications: Hypersensitivity to the active substance or any of the other ingredients. Undesirable effects: Very common: anemia, serous retinopathy, high blood pressure, bleeding, nausea, vomiting, light sensitivity, maculopapular rash, acne-like rash, hyperkeratosis, fever, increased liver enzymes, increase in CPK. Common: cutaneous basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, dehydration, hypophosphatemia, hyponatremia, hyperglycemia, pneumonitis, chills, decreased ejection fraction, increased blood bilirubin. Warnings: Before starting to use Cotellic in combination with vemurafenib, patients must have BRAF V600 mutation-positive tumour status confirmed by a validated test. Consult your doctor before taking this medicine if you have eye, heart or liver problems. Consult your doctor immediately if you get diarrhea. Keep out of the sight and reach of children. Contains lactose. Dosage: The recommended dose of Cotellic is 3 tablets (a total of 60 mg) once daily. 21-day treatment cycle followed by a 7 day treatment break. Prescription-only medicine. See detailed prescribing information. Marketing authorisation holder: Roche Registration Limited, Welwyn Garden City, United Kingdom. Further information available on request. Representative in Germany: Roche Pharma AG, 79630 Grenzach-Wyhlen. Revision date: December 2015
Reference1. Larkin J, et al. N Eng J Med 2014; 371:1867-1876.
For further information, please visit www.roche-cotellic.com PR/COBI/1604/0006 April 2016
REGISTRATION FORMJune 30th–July 1st, 2016 · 6 th European Post-Chicago Melanoma / Skin Cancer Meeting 2016 Results and Interpretations of ASCO Presentations 2016: Interdisciplinary Global Conference on News in Melanoma/Skin Cancer
First Name: Last Name:
Professional Title: Degree: MD PhD RN PA-C Other
Gender: Male Female Speciality:
Institution: Address:
City: State: Zip Code: Country:
Daytime Telephone: Fax: E-Mail:
Fees (VAT included)
Early registration till April 5th
From April 6th till June 19th
On site
Full Delegates 300 Euro 400 Euro 500 Euro
Doctors in training* and Eastern European Countries 200 Euro 250 Euro 300 Euro
Day Ticket June 30th July 1st 150 Euro 200 Euro 250 Euro
*Please forward appropriate documentary evidence via mail, email or fax to the congress office: MedConcept GmbH, Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany, [email protected], Fax: +49 (0)3342 42689-40
Total Amount: Euro
Payment Method
Bank Transfer:
Credit Card: MasterCard Visa American Express
Credit Card Number:
Expiration Date:
Security Code CCV: (MC/Visa – 3 digits on back, AMEX – 4 digits on front)
Cardholder Name:
Signature:
Congress Organization
Gesellschaft für medizinische Projekte mbHFriedenstraße 58 · 15366 Neuenhagen bei Berlin [email protected] · www.medconcept.org Phone +49 (0)3342 42689-30 · Fax +49 (0)3342 42689-40
24
25
NOTES
26
bms-onkologie.de/immunonkologie
OPDIVO® 10 mg/mL concentrate for solution for infusion. Active substance: nivolumab. Excipients: sodium citrate dihydrate, sodium chloride, mannitol (E421), pentetic acid, polysorbate 80, sodium hydroxide, hydrochloric acid and water for injections. Therapeutic indications: Melanoma: OPDIVO® as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Non-small cell lung cancer (NSCLC): OPDIVO® is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. Renal cell carcinoma (RCC): OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. Contra indications: Hypersensitivity to the active substance or to any of the excipients. Further information: If Nivolumab is used in combination with ipilimumab, read the prescribing information for ipili-mumab before the start of treatment. When nivolumab has been used in combination with ipilimumab, immune-related adverse reactions have been observed at higher frequencies compared with nivolumab monotherapy. Patients should be closely monitored (at least up to 5 months after the last dose), as adverse reactions with nivolumab or nivolumab in combination with ipilimumab may occur at any time during or after treatment. Adverse reactions: Very common: decreased appetite, diarrhoea, nausea, skin rash, pruritus, fatigue, hypocalcaemia, lymphopenia, leukopenia, thrombocytopenia, anaemia, hyper kalaemia, hypomagnesaemia, hyponatraemia, abnormal laboratory values. Nivolumab monotherapy: hypercalcaemia, hypokalaemia. Nivolumab in combination with ipilimumab: hypo-thyroidism, headache, colitis, vomiting, abdominal pain, arthralgia, pyrexia, neutropenia, hypocalcaemia. Common: infection of the upper respiratory tract, infusion-related reaction, hypersensitivity, hyperthyroidism, hyperglycaemia, peripheral neuropathy, dizziness, blurred vision, hypertension, pneumonitis, dyspnoea, cough, stomatitis, constipation, dry mouth, vitiligo, dry skin, erythema, alopecia, musculoskeletal pain, oedema (including peripheral oedema), hypermagnesaemia, hypernatraemia, weight loss. Nivolumab monotherapy: hypothyroidism, headache, dry eyes, colitis, vomiting, abdominal pain, arthralgia, pyrexia, neutropenia. Nivolumab in combination with ipilimumab: pneumonia, eosinophilia, adrenal insu� ciency, hypopituitarism, hypophysitis, thyroiditis, dehydration, hepatitis, uveitis, tachycardia, pulmonary embolism, gastritis, urticaria, renal failure, pain, hypercalcaemia. Uncommon: bronchitis, diabetic ketoacidosis, pleural e� usion, pancreatitis, psoriasis, arthritis, tubulointerstitial nephritis, pain in the chest. Nivolumab monotherapy: pneumonia, anaphylactic reaction, adrenal insu� ciency, hypopituitarism, hypophysitis, thyroiditis, dehydration, metabolic acidosis, hepatitis, hyperbilirubinaemia, polyneuropathy, uveitis, tachycardia, vasculitis, erythema multiforme, rosacea, urticaria, polymyalgia rheumatica, renal failure, pain. Nivolumab in combination with ipilimumab: sarcoidosis, diabetes mellitus, Guillain-Barré syndrome, polyneuropathy, neuritis, peroneal paralysis, autoimmune neuropathy (including facial nerve and sixth nerve palsy), arrhythmia (including ventricular arrhythmia), atrial fi brillation, bowel perforation, duodenitis, spondyloarthropathy, Sjogren’s syndrome, myopathy. Rare: toxic epidermal necrolysis. Nivolumab monotherapy: histiocytic necrotising lymphadenitis (Kikuchi lymphadenitis), eosinophilia, diabe-tes mellitus, cholestasis, Guillain-Barré syndrome, demyelination, myasthenic syndrome, autoimmune neuropathy (including facial nerve and sixth nerve palsy), arrhythmia (including ventricular arrhythmia), atrial fi brillation, pulmonary infi ltration, gastritis, duodenal ulcer, myopathy
For further information, see the Summary of Product Characteristics (SmPC). Medicinal product subject to medical prescription. This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Marketing authorisation holder: Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom. Status of text: v5 current prescribing information
Strong individually.Highly e� ective in combination.
Now approved for patients with advanced melanoma
starting from fi rst-line
regardless of BRAF and PD-L1 status*, 1
* OPDIVO® as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression.1
1. OPDIVO® Summary of Product Characteristics, current version
